Industry news round-up: updates from February 2025
Explore the latest advancements in real-world data (RWD), real-world evidence (RWE) and health technology assessment (HTA) as featured on The Evidence Base during February 2025.
Flatiron Health and Exact Sciences drive innovation in MRD testing through RWE
Flatiron Health and Exact Sciences have partnered to advance molecular residual disease (MRD) research by leveraging RWE, evaluating the Oncodetect™ test’s ability to detect ctDNA and predict cancer recurrence in a broad range of solid tumors.
Trinetx and Fujitsu partner to advance real-world evidence in Japan
TriNetX and Fujitsu have formed TriNetX Japan K.K. to enhance RWE by integrating anonymized electronic health record (EHR) data into a global research network, supporting clinical trials and healthcare innovation.
DATA-CAN and Arcturis form partnership to advance oncology RWE
DATA-CAN, the UK’s Health Data Research Hub for Cancer, has announced a new partnership with Arcturis to enhance the use of RWE in cancer research.
New partnership between Aetion and Crohn’s & Colitis Foundation to enhance real-world IBD research
Aetion will leverage its RWE platform to analyze the Crohn's & Colitis Foundation's IBD Plexus® data, advancing insights and targeted treatment development for inflammatory bowel disease (IBD).
Atropos Health partners with Emory Healthcare to leverage real-world evidence for data-driven medication decisions
Emory Healthcare has announced a partnership with Atropos Health to use RWE and AI-driven analytics to enhance medication decision-making, optimize drug protocols, and improve patient care.
Verana Health and Nanoscope Therapeutics to advance retinitis pigmentosa research with real-world data in new partnership
Verana Health and Nanoscope Therapeutics have announced a strategic collaboration to accelerate research on the rare eye disease retinitis pigmentosa (RP) using RWD. Leveraging Verana’s proprietary Qdata® and Nanoscope’s expertise in gene therapy, the partnership aims to enhance insights into disease progression and treatment efficacy, advancing therapeutic development for RP patients.
Europe opens first submission period for joint scientific consultations under HTA regulation
European Commission officially marks opening of the first request submission period for joint scientific consultations (JSCs) under the new Health Technology Assessment Regulation (HTAR), marking a significant milestone in the implementation of the HTAR, which came into effect on January 12, 2025.
NICE, ICER and Canada’s Drug Agency launch international initiative to advance HTA methodologies
The Health Economics Methods Advisory (HEMA) will bring together global experts to evaluate and refine HTA methods through independent research, evidence-based guidance, and educational initiatives.
UK’S NICE launches new initiative to streamline health technology approval and improve patient access
The Medicines and Medical Devices (MMD) Access Initiative, a newly established cross-government working group, aims to enhance coordination between regulatory, HTA, and commercial processes within the four UK nations.
UK's refreshed Innovative Licensing and Access Pathway (ILAP) provides a more integrated approach to patient access
The UK’s Innovative Licensing and Access Pathway (ILAP) has been updated to provide a clearer, more streamlined, and integrated approach to supporting access to transformative medicines for patients in the NHS.
| Register for free today to become a member of The Evidence Base and receive the latest news straight to your inbox. |